DermTech Announces Publication of New Clinical Research on GvHD Conducted in Collaboration with Memorial Sloan Kettering Cancer Center

0

LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a noninvasive skin genomics platform, today announced the publication from “Noninvasive Genomic Characterization of Patients with Chronic Nonsclerotic and Superficially Sclerotic Cutaneous Graft-vs-Host Disease Identified a Novel Genetic Signature in Responders to Ruxolitinib Cream,” in Transplantation and Cellular Therapy.

Graft versus host disease (GvHD) occurs when the immune cells of the transplanted donor attack healthy cells and tissues of the recipient. Dermatological manifestations are an important aspect of GvHD, as they are often the first organ affected in GvHD and develop in more than half of patients with GvHD. While oral ruxolitinib, a JAK1/2 inhibitor, has been approved by the US Food & Drug Administration (FDA) for the treatment of acute and chronic GvHD (cGvHD), this is the first clinical trial evaluating the efficacy of topical ruxolitinib in cutaneous GvHD patients.

Skin samples were collected non-invasively from patients with cutaneous GvHD using the DermTech Smart StickerMT and then analyzed by RNA sequencing to study the effect of topical ruxolitinib on gene expression in cGvHD. Specifically, the study assessed genomic differences between treatment with ruxolitinib cream and vehicle cream and the distinction between patients who responded to treatment and those who did not.

“Noninvasive characterization and prognosis of therapeutic response is necessary for GvHD therapies,” said Dr. Alina Markova, lead author and assistant dermatologist at Memorial Sloan Kettering Cancer Center. “This is the first study to characterize the effect of topical JAK1/2 blockade with ruxolitinib cream on cutaneous GVHD and to differentiate genomic signatures between responders and non-responders.”

Bioinformatics analyzes of Smart StickerMT collected skin samples successfully identified 210 differentially expressed genes (DEGs) between topical ruxolitinib and in-vehicle treatments with primary pathway differences in immune modulation and cell signaling. Additionally, 383 DEGs have been identified that differentiate patients who responded to treatment from those who did not.

“We are proud to partner with Memorial Sloan Kettering Cancer Center to advance research into the treatment of patients with cutaneous GvHD and provide clinicians with objective genomic information to help identify patients who may benefit from treatment,” said Michael Howell, PhD, Chief Scientific Officer of DermTech. “This collaboration once again demonstrates DermTech Stratum’s capabilities to offer translational medicine services to bring greater precision and personalization to the diagnosis and treatment of dermatological diseases.

For more information about DermTech Stratum, visit https://dermtechstratum.com/.

About DermTech:

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, made possible by its non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions of people by providing non-invasive, precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of non-invasively collected skin samples using our smart stickersMT. DermTech markets and develops products that facilitate the early detection of skin cancers and develops products that assess inflammatory diseases and personalize drug treatments. For more information, please visit DermTech.com.

Forward-looking statements:

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. DermTech’s expectations, estimates and projections may differ from its actual results and, therefore, , you should not rely on these forward-looking statements as predictions of future events. Words such as “expect”, “estimate”, “project”, “budget”, “expect”, “anticipate”, “intend”, “plan”, “may”, “will” , “could”, “should”, “believes”, “predicts”, “potential”, “continues” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, but are not limited to, expectations and assessments regarding: performance, benefits to patients, benefits to research partners and collaborators, cost-effectiveness, product commercialization and adoption, and DermTech’s services and market opportunities for such products, and DermTech’s ability to expand its product and service offerings and develop products under development. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are beyond DermTech’s control and are difficult to predict. Factors that could cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be brought against DermTech; (2) DermTech’s ability to obtain additional financing to develop and commercialize its products and services; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) reimbursement for DermTech tests by Medicare and private payers; (5) the ability of patients or healthcare providers to obtain sufficient coverage or reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain key employees; (7) changes in applicable laws or regulations; (8) market adoption and demand for DermTech’s products and services, as well as the possibility that DermTech may be adversely affected by other economic, business and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of DermTech’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), and ( (y) other documents filed or to be filed by DermTech with the SEC, including any subsequent filings. DermTech cautions that the above list of factors is not exclusive. You should not place undue reliance on forward-looking statements, which speak only as of the date made. DermTech neither undertakes nor accepts any obligation or undertaking to issue updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. .

Share.

Comments are closed.